A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD)

Journal of the American Medical Directors Association

Volumn 16, Issue 4, 2015, Pages 316-322

  Ballard, Clive ^a   Thomas, Alan ^b   Gerry, Stephen ^c   Yu, Ly Mee ^d   Aarsland, Dag ^e   Merritt, Claire ^f   Corbett, Anne ^a   Davison, Christopher ^b   Sharma, Narenda ^b   Khan, Zunera ^a   Creese, Byron ^a   Loughlin, Paul ^f   Bannister, Carol ^f   Burns, Alistair ^g   Win, Soe Nyunt ^h   Walker, Zuzana ⁱ   Ferreira, Nicola ^j   Koranteng, Paul ^j   Vanderputt, Rohan ^j   Akinola, Mary ^j   Martos, Lola ^j   Adams, Justine ^j   Dransfield, Chrissie ^j   Pavey, Malika ^j   Collicott, Nathan ^j   Hall, Claire ^j   Rigby, Lynn ^j   Warr, Lianne Danielle ^j   Leontis, Marianna ^j   Shora, Shaheen ^j   Bhan Kotwal, Shefalica ^j   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h University College London ^*  (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j NONE

more..

Author keywords

Alzheimer; Antipsychotic; Dementia; Memantine; Neuropsychiatric; Withdrawal

Indexed keywords

MEMANTINE; NEUROLEPTIC AGENT;

AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONG TERM CARE; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SAFETY; PROSPECTIVE STUDY; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT WITHDRAWAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LONG-TERM CARE; MALE; MEMANTINE; PATIENT SAFETY; PROSPECTIVE STUDIES; PSYCHOMOTOR AGITATION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; WITHHOLDING TREATMENT;

EID: 84934434539     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2014.11.002     Document Type: Article

References (34)

1. Alzheimer's Disease International. World Alzheimer Report. 2009. Available at:. Accessed December 2, 2012. http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf.
2. Steinberg M., Shao H., Zandi P., et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The Cache County Study. Int J Geriatr Psychiatry 2008, 23:170-177.
3. National Institute for Health and Clinical Excellence (NICE). Dementia: Supporting people with dementia and their carers in health and social care. Available at:. 2006. Accessed June 16,2014. https://www.nice.org.uk/guidance/cg42.
4. Lyketsos C.G., Colenda C.C., Beck C., et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006, 14:561-572.
5. Alzheimer's Society Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. Available at:. 2012. Accessed April 23,2014. http://www.alzheimers.org.uk/bpsdguide.
6. Ballard C., Howard R. Neuroleptic drugs in dementia: Benefits and harm. Nature Rev Neurosci 2006, 7:492-500.
7. Schneider L.S., Dagerman K., Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006, 14:191-210.
8. Ballard C.G., Gauthier S., Cummings J.L., et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009, 5:245-255.
9. Ballard C., Creese B., Corbett A., Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert opinion on drug safety 2011, 10:35-43.
10. Barnes T.R., Banerjee S., Collins N., et al. Antipsychotics in dementia: Prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry 2012, 201:221-226.
11. Ballard C., Margallo-Lana M., Juszczak E., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ 2005, 330:874.
12. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Nature reviews Neuroscience. NEngl J Med 2006, 355:1525-1538.
13. Bridges-Parlet S., Knopman D., Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: Results of a double-blind, baseline-treatment-controlled pilot study. JGeriatr Psychiatry Neurol 1997, 10:119-126.
14. Ballard C.G., Thomas A., Fossey J., et al. A3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome. JClin Psychiatry 2004, 65:114-119.
15. Ballard C., Lana M.M., Theodoulou M., et al. Arandomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008, 5:e76.
16. Ballard C., Hanney M.L., Theodoulou M., et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009, 8:151-157.
17. Devanand D.P., Pelton G.H., Cunqueiro K., et al. A6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry 2011, 26:937-943.
18. Devanand D.P., Mintzer J., Schultz S.K., et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. NEngl J Med 2012, 367:1497-1507.
19. Fossey J., Ballard C., Juszczak E., et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: Cluster randomised trial. BMJ 2006, 332:756-761.
20. Cohen-Mansfield J., Lipson S., Werner P., et al. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: A controlled, double-blind study. Arch Intern Med 1999, 159:1733-1740.
21. Ballard C., Margallo-Lana M., O'Brien J.T., et al. Top cited papers in International Psychogeriatrics: 6a. Quality of life for people with dementia living in residential and nursing home care: The impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. Int Psychogeriatr/IPA 2009, 21:1026-1030.
22. Fox C., Crugel M., Maidment I., et al. Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial. PLoS One 2012, 7:e35185.
23. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006, CD003154.
24. Wilcock G.K., Ballard C.G., Cooper J.A., Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies. JClin Psychiatry 2008, 69:341-348.
25. Howard R., McShane R., Lindesay J., et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. NEngl J Med 2012, 366:893-903.
26. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
27. Cohen-Mansfield J., Marx M.S., Rosenthal A.S. Adescription of agitation in a nursing home. JGerontol 1989, 44:M77-M84.
28. Byrne L.M., Wilson P.M., Bucks R.S., et al. The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease. Int J Geriatr Psychiatry 2000, 15:656-661.
29. Cummings J.L., Mega M., Gray K., et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
30. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 1975, 12:189-198.
31. Ballard C., McKeith I., Burn D., et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997, 96:366-371.
32. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11:S22-S32.
33. Auer S., Reisberg B. The GDS/FAST staging system. Int Psychogeriatr/IPA 1997, 9:167-171.
34. Health & Social Care Information Centre. National Dementia and Antipsychotic Prescribing Audit. Available at:. 2012. Accessed September 8,2014. http://www.hscic.gov.uk/dementiaaudit.